AI Architecture Advisory in a Biopharma Environment

The Challenge

In pharma, the question about AI is rarely one of feasibility. The models can do what is needed. The question is which processes may be automated at all - and what an approval looks like that withstands scrutiny.

Our client wanted a dependable view of where agent systems make sense and are permissible, before investing. Not a list of possibilities, but a prioritised assessment with the regulatory constraints set alongside it.

Our Approach

Process capture before technology assessment. We mapped the existing workflows and identified automation potential - deliberately without committing to a technology up front. Some of what looked like an AI problem turned out to be a rules question.

Approval precheck as an architectural pattern. The central proposal was not a model but a pattern: every automatically generated output passes through an upstream check layer before being presented to a human for approval. That shifts control from trust in the model to an explicit, auditable layer in front of it.

Regulation as a design parameter. Data protection and regulatory requirements were not treated as a downstream review but as a constraint shaping the architecture - particularly around data residency, traceability, and the question of which data a model may see at all.

Prepared for decision-makers. The output was deliberately not a technical document but a basis for decision: prioritised use cases with effort, benefit and regulatory classification.

The Results

The client has a dependable basis for which use cases to tackle first - and for which the regulatory clarification has to precede the technical effort.

The approval precheck pattern applies well beyond its original occasion. It answers the question that precedes every AI initiative in a regulated industry: who is accountable for what the system produces - and how is that demonstrated?